Skip to content

Effect of EECP on Anterior Ischemic Optic Neuropathy

Study of the Effect of EECP on Anterior Ischemic Optic Neuropathy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01768260
Acronym
AION
Enrollment
40
Registered
2013-01-15
Start date
2012-12-31
Completion date
2018-03-31
Last updated
2017-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Ischemic Optic Neuropathy

Keywords

visual acuity, artery flow velocity, Enhanced External Counterpulsation, Ischemic, Optic Neuropathy

Brief summary

Enhanced External Counterpulsation(EECP) therapy may promote the recovery of visual function by improving the blood perfusion of eyes. The present study aims to investigate the effect of EECP on Anterior Ischemic Optic Neuropathy.

Detailed description

Patients with Anterior Ischemic Optic Neuropathy are randomized into two groups: one group receive standard medical treatment for ischemic optic neuropathy, the other group plus EECP therapy besides standard medical treatment.

Interventions

EECP is performed for 1 hours every day, for a total of 36 hours.

DRUGAspirin

Standard drug therapy

Sponsors

First Affiliated Hospital, Sun Yat-Sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* ischemic optic neuropathy * within 1 month

Exclusion criteria

* Hemorrhagic disease * thrombophlebitis or infection lesions * severe hypertensive patients * Atrial fibrillation * Aortic regurgitation

Design outcomes

Primary

MeasureTime frame
visual acuity7 weeks

Secondary

MeasureTime frame
Ophthalmic artery blood flow velocity7 weeks

Other

MeasureTime frame
Central retinal artery flow velocity7 weeks

Countries

China

Contacts

Primary ContactYan Zhang, MD
Zhyan3@mail.sysu.edu.cn862087755766

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026